Evaluation of the Feasibility of Personalized and Preventive Support for COGnitive Complaints, by a Paramedical Caregiver in Women Suffering From Non-Metastatic Breast Cancer, Requiring Chemotherapy (EFACog).

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

EFACog is a single-center prospective cohort feasibility study conducted on a single group of patients to study the feasibility of a personalized support program by a nurse conducted over 9 months, using face-to-face and telephone interviews. The objective of this support program is to prevent the occurrence of post-chemotherapy cognitive impairment. After a pre-inclusion visit, patients with no pre-existing cognitive impairment will be included in the study and will receive a 9-month follow-up after the first course of chemotherapy. All follow-up visits (telephone or face-to-face) will be scheduled in conjunction with those taking place in the care setting.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Age 18 to 65;

• WHO 0 to 1;

• Patient newly diagnosed with breast cancer (unilateral or bilateral);

• Patient with a MoCA score not revealing proven cognitive disorders (MoCA ≥ 26/30 and a QPC score \<3, without a YES answer to question 5 and without 2 YES answers to questions A, 4, 5, 7, 8 of the questionnaire);

• Patient to receive adjuvant or neo-adjuvant chemotherapy;

• Patient having understood, signed and dated the consent form

• Affiliated to a social security system

Locations
Other Locations
France
Institut de Cancérologie de Lorraine
RECRUITING
Vandœuvre-lès-nancy
Contact Information
Primary
MERLIN JEAN LOUIS, PharmD, PhD
jl.merlin@nancy.unicancer.fr
+ 33 3 83 65 60 62
Backup
BOUJEDAINI NAOUAL, PhD.
n.boujedaini@nancy.unicancer.fr
+33 3 83 59 86 68
Time Frame
Start Date: 2024-08-01
Estimated Completion Date: 2027-08-01
Participants
Target number of participants: 50
Treatments
Experimental: Personalized support program
Related Therapeutic Areas
Sponsors
Leads: Institut de Cancérologie de Lorraine

This content was sourced from clinicaltrials.gov